What do the U.S. rules say?

In compounding, a pharmacist, doctor or facility recorded with FDA prepares a medicine in place of a ready-made product supplied by a drug company.

Compounded drugs have no FDA approval; before they go on sale, FDA does not check them for safety, quality or effect.

Compounding can meet a patient need, but its rules still restrict which raw ingredients can be used.

FDA’s warning page lists Selank among ingredients that people had asked it to allow for making medicines. Those requests were taken back.

April 22, 2026 is the date FDA gives for the page’s information. FDA does not give the date when the Selank request was taken back.

Taking back the request did not give permission to make Selank medicines. FDA still prints its concerns about harm beside Selank’s name.

The official ingredient list allows certain raw ingredients for ordinary pharmacy compounding. FDA also groups ingredients it is considering on separate review lists.

Checks in September 2026 found Selank on neither the official ingredient list nor FDA’s review lists for pharmacies and medicine-making facilities.

These lists concern ingredients used to make medicines. They do not list extra things added to a Selank shot.

Taking back a request does not satisfy the ingredient rules for ordinary pharmacy compounding.

An ingredient covered by an official quality standard must satisfy it along with the pharmacy compounding standards. Without that quality standard, the ingredient has to be used in a drug approved by FDA. If neither route fits, the official ingredient list must include it.

A valid report certifying the ingredient’s contents is also required, and its maker must be registered with FDA.

Ask the pharmacy which rule it relies on for the proposed Selank shot and how it meets that rule. Ask for the answer in writing and check the FDA links below.